Effect of L-carnitine on insulin resistance

Evaluation the effect of L-carnitine on insulin resistance and prognosis of patients with ischemic stroke admitted to the Intensive Care Unit of Alzahra hospital: randomized, double blinded clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200509047365N1

Enrollment

Registered

2020-06-02

Start date

2019-04-21

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke. Cerebral infarction

Interventions

Intervention 1: Intervention group: L-carnitine 250 mg of Pursina Company, two tablets every 8 hours for six days orally or via nasogastric tube (NGT). Intervention 2: Control group: Placebo of Pursin

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age of 18 years or older Diagnosis of ischemic stroke

Exclusion criteria

Exclusion criteria: A diagnosis of hemorrhagic stroke History of hypersensitivity to L-carnitine History of taking L-carnitine in the last month Required dialysis

Design outcomes

Primary

Measure	Time frame
Determination and comparison of mean insulin resistance before and after intervention. Timepoint: Before intervention and 7 days after intervention. Method of measurement: Homeostatic model assessment of insulin resistance (HOMA-IR).;Determination and comparison of Prognosis of two groups. Timepoint: Daily from day 1, before intervention to day 7 and 28 days after intervention. Method of measurement: Frequency of 28-day mortality and duration of mechanical ventilation, daily Glasgow Coma Scale and Sequential Organ Function Assessment scores, whether or not sepsis occurs through the intervention days based on SOFA score changes.	—

Measure

Time frame

Determination and comparison of mean insulin resistance before and after intervention. Timepoint: Before intervention and 7 days after intervention. Method of measurement: Homeostatic model assessment of insulin resistance (HOMA-IR).;Determination and comparison of Prognosis of two groups. Timepoint: Daily from day 1, before intervention to day 7 and 28 days after intervention. Method of measurement: Frequency of 28-day mortality and duration of mechanical ventilation, daily Glasgow Coma Scale and Sequential Organ Function Assessment scores, whether or not sepsis occurs through the intervention days based on SOFA score changes.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMalihe Nejati

Esfahan University of Medical Sciences

nejati@pharm.mui.ac.ir+98 31 3792 7071

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026